Skip to main content
TipRanks
Go Ultimate75% OFF

Terumo (4543) Q2 2027 Earnings Report

6 Followers

JP:4543 Q2 2027 EPS Results

Actual EPS
-JPY 10.72
Consensus EPS
-JPY 1.33
Beat/Miss
Missed by -JPY 9.39
One Year Ago EPS
JPY 23.76

JP:4543 Q2 2027 Revenue Results

Actual Revenue
JPY 312.69B
Expected Revenue
JPY 306.41B
Beat/Miss
Beat by +JPY 6.28B
YoY Revenue Growth
+13.72%

Earnings Announcement Details

Quarter
Q2 2027
Date
11/12/2026
Time
Before Open
Conference Call
Thursday, November 12, 2026
JP:4543 Upcoming Earnings

Terumo's next earnings date is estimated for February 10, 2027, based on past reporting schedules.

Q2 2027 Earnings Call Audio

JP:4543 Q2 2027 Earnings Call
0:00 / 0:00

Q2 2027 Earnings Slide Deck

Q2 2027 Earnings Call Summary

Q2 2027
Earnings Call Date:Nov 12, 2026|% Change Since:-0.32%|
Earnings Call Sentiment|Neutral

The call reflected strong underlying operating momentum, including record first-half revenue and adjusted operating profit, broad core-business growth, and positive long-term initiatives in TBCT, Neuro, Organ Technologies, and CDMO. However, the sentiment was tempered by the Terumo Aortic recall, unresolved manufacturing issues, substantial asset-valuation and impairment risks, the CSL Plasma agreement termination, temporary Neuro supply constraints, and significant reductions to reported operating-profit and revenue guidance. Overall, the positive core-business performance and adjusted-profit growth were balanced by material one-time charges and operational uncertainty.

Company Guidance

For FY '26, Terumo lowered its revenue forecast by JPY 10 billion to JPY 219.5 billion, operating profit forecast by JPY 41 billion to JPY 119 billion, and expects profit of the year to be JPY 87.5 billion; adjusted operating profit was lowered by JPY 3 billion from the August guidance to JPY 271.5 billion, representing 24% growth year-over-year with an adjusted OP margin of 22%. The Terumo Aortic voluntary recall is expected to have a negative impact of approximately JPY 8 billion on revenue and JPY 41 billion on operating profit, while TBCT expects FY '27 revenue growth of 5% or more and is targeting an AOP increase of JPY 5 billion or more from its FY '26 guidance announced in August, with Reveos addressing a serviceable addressable market of approximately $1.2 billion in FY '26; Organ Technologies’ full year profit margin target of 20% remains unchanged.

  • Record First-Half Revenue and Adjusted Operating ProfitFirst-half revenue reached a record JPY 624.5 billion, increasing 17% year-over-year and 8% on a local-currency basis, driven by solid core-business performance, strong demand in the Americas and Asia, and favorable foreign-exchange movements. Adjusted operating profit also reached a record high of JPY 147.3 billion, up 29% year-over-year, supported by revenue growth and positive pricing effects.
  • Core Business Growth Remains StrongManagement said underlying earnings power continued to grow steadily, supported by continued growth in core businesses. TIS and Global Blood Solutions led revenue growth, while other core businesses performed solidly overall. Adjusted operating profit guidance remains JPY 271.5 billion, representing 24% year-over-year growth, with an adjusted operating margin of 22%.
  • Cardiac and Vascular Growth Outside AorticCardiac and Vascular revenue grew 6% on a local-currency basis, led by key TIS products, particularly in the Americas and Asia. Oncology and endovascular portfolios performed well, cardiovascular demand remained solid in North America and Asia, and the cerebral aneurysm treatment business led by WEB continued to grow in Japan and Europe. The C&V profit margin reached 30%, supported by higher sales, pricing initiatives, and tariff-refund benefits.
  • Blood and Cell Technologies Delivered Steady GrowthTBCT revenue grew at a 14% CAGR from FY '21 through FY '25, or 5% on a local-currency basis, excluding Plasma Innovations. Trima Accel is a market leader in more than 130 countries, Spectra Optia is described as the gold standard for stem-cell collection worldwide, and Reveos serves more than 70 countries. In the first half, blood-collection products including Trima and Reveos performed well, Global Therapy Innovations maintained strong growth in Europe, the U.S. and Asia, and TBCT's profit margin was 17%.
  • TBCT Growth Initiatives and FY '27 TargetsFor FY '27, management expects TBCT revenue growth of 5% or more and is targeting an AOP increase of JPY 5 billion or more from the FY '26 guidance announced in August. Key initiatives include increasing Reveos utilization and expanding into new geographies, broadening Spectra Optia adoption across disease states and geographies, and improving productivity and cost efficiency through global supply-chain optimization.
  • Continued Investment in TBCT Infrastructure and Digital CapabilitiesTBCT plans to modernize infrastructure and leverage digital technologies, AI, and advanced analytics to improve efficiency, resilience, and scalability. Management also stated that operational-excellence initiatives are intended to support growth and drive continued margin improvement.
  • Arsenal Medical Acquisition CompletedTerumo completed the Arsenal Medical acquisition on October 2 for approximately $250 million plus contingent consideration tied to specified milestones. The acquisition added NeoCast, a next-generation liquid embolic agent designed for middle meningeal artery embolization for chronic subdural hematoma, expanding Terumo Neuro's portfolio beyond cerebral aneurysm and acute ischemic stroke into adjacent treatment areas.
  • Organ Technologies Maintained Strong First-Half GrowthOrgan Technologies revenue was JPY 11.6 billion in the first half, up 36% year-over-year. Management said the organ-preservation market using normothermic machine perfusion continues to expand with the growing number of liver transplants, and the company expects to continue to outpace market growth. The full-year profit-margin target of 20% remains unchanged.
  • Medical Care Solutions Revenue Growth and CDMO ProgressMedical Care Solutions revenue growth was driven by Hospital Care Solutions and Pharmaceutical Solutions. Hospital Care Solutions benefited from drug-price revisions in Japan and solid key-product sales, while Pharmaceutical Solutions grew through PLAJEX and kitting products, particularly in Asia and Europe. The Leverkusen plant's pre-filled syringe line launch in the second half of FY '27 is progressing as planned, and discussions with multiple pharmaceutical companies in Europe and the U.S. are progressing.
  • Regional Demand Remained Broadly SupportiveThe Americas benefited from continued TIS demand, Organ Technologies growth, and solid performance from TCV and Global Blood Solutions. Europe saw steady Neuro growth, strong PLAJEX and kitting-product sales, and double-digit Global Blood Solutions growth. Japan growth was led by Hospital Care Solutions, Neuro, and Pharmaceutical Solutions, while Asia growth was led by C&V, particularly TIS and TCV.
  • Underlying Business Outlook Remains SupportedManagement stated that the revised plan includes various negative factors and that at least most of them have been covered. The company does not assume many negative factors for its actual business and did not make major changes to adjusted operating profit guidance. Management also expects the Neuro issue to be temporary, with workforce secured and training underway, and expects no impact next year from the current Neuro supply constraint.
  • Portfolio Transformation and Long-Term StrategyManagement said it will continue evaluating businesses based on global growth potential, profitability, and capital efficiency, while making necessary portfolio decisions without slowing the pace of transformation. Terumo plans to present its next five-year growth strategy, GS31, on December 15.

JP:4543 Earnings History

JP:4543 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 10, 20272027 (Q3)12.65-22.14――
Nov 12, 20262027 (Q2)-1.33-10.7223.76-145.12% (-34.48)
Aug 07, 20262027 (Q1)25.8947.7428.3768.28% (+19.37)
May 15, 20262026 (Q4)15.0117.8712.4843.19% (+5.39)
Feb 13, 20262026 (Q3)22.5722.1423.96-7.60% (-1.82)
Nov 12, 20252026 (Q2)24.5023.7619.7520.30% (+4.01)
Aug 07, 20252026 (Q1)24.4028.3722.8224.32% (+5.55)
May 14, 20252025 (Q4)20.7512.4817.82-29.97% (-5.34)
Feb 13, 20252025 (Q3)25.6323.9620.0319.62% (+3.93)
Nov 07, 20242025 (Q2)22.1219.7518.56.79% (+1.25)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed